Related Experiment Video
Updated: Mar 7, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
Summary
Ceritinib shows promise as a first-line treatment for ALK-positive non-small cell lung cancer, outperforming chemotherapy. However, toxicity concerns may favor next-generation inhibitors like alectinib for untreated patients.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- ALK-positive non-small cell lung cancer (NSCLC) is a distinct subtype.
- Chemotherapy remains a standard first-line treatment for advanced NSCLC.
- Targeted therapies offer improved outcomes for specific patient populations.
Purpose of the Study:
- To evaluate ceritinib as a first-line treatment for ALK-positive NSCLC.
- To compare the efficacy and safety of ceritinib against chemotherapy.
- To assess the potential of next-generation ALK inhibitors in this setting.
Main Methods:
- Phase III clinical trial design.
- Comparison of ceritinib versus standard chemotherapy.
- Assessment of efficacy endpoints (e.g., progression-free survival) and safety profiles.
Main Results:
- Ceritinib demonstrated superior efficacy compared to chemotherapy in the first-line setting.
- Significant toxicity issues were observed with ceritinib treatment.
- Alectinib, a next-generation ALK inhibitor, emerged as a potential preferred option.
Conclusions:
- Ceritinib represents a potential new first-line option for ALK-positive NSCLC.
- Toxicity remains a significant consideration for ceritinib.
- Alectinib may be a more favorable choice for untreated patients due to its profile.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
701
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
701